Compare NGL & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NGL | TSHA |
|---|---|---|
| Founded | 1940 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.8B |
| IPO Year | 2011 | 2020 |
| Metric | NGL | TSHA |
|---|---|---|
| Price | $17.64 | $5.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $11.63 |
| AVG Volume (30 Days) | 228.6K | ★ 1.9M |
| Earning Date | 05-28-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5.56 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,156,159,000.00 | $9,773,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,152.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 17.28 |
| 52 Week Low | $5.72 | $2.72 |
| 52 Week High | $19.06 | $7.30 |
| Indicator | NGL | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 53.22 | 32.59 |
| Support Level | $15.02 | $4.37 |
| Resistance Level | $18.62 | $6.01 |
| Average True Range (ATR) | 0.79 | 0.24 |
| MACD | -0.07 | -0.08 |
| Stochastic Oscillator | 62.05 | 9.92 |
NGL Energy Partners LP is a USA-based firm that owns and operates a vertically integrated energy business. The company's operating segments include Crude Oil Logistics, Water Solutions, and Liquids Logistics. It operates crude oil Logistics, owns pipeline injection stations, and offers services for the treatment and disposal of wastewater generated from crude oil and natural gas production, as well as for the disposal of solids, such as tank bottoms and drilling fluids. The firm also supplies natural gas liquids to retailers, wholesalers, refiners, and petrochemical plants and sells propane and distillates.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.